| Bioactivity | Ganirelix acetate (Ganirest) is an injectable competitive gonadotropin-releasing hormone (GnRH) antagonist. Ganirelix acetate directly competes against the endogenous molecule for receptor binding, and causes a rapid reduction in estradiol levels. Ganirelix acetate can be used for researching ovarian hyperstimulation syndrome (OHSS)[1]. |
| Target | GnRH |
| Name | Ganirelix acetate |
| CAS | 129311-55-3 |
| Formula | C84H121ClN18O17 |
| Molar Mass | 1690.42 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, protect from light, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen) |
| Reference | [1]. Gustofson RL, et al. Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome. Hum Reprod. 2006 Nov;21(11) |
Ganirelix acetate
CAS: 129311-55-3 F: C84H121ClN18O17 W: 1690.42
Ganirelix acetate (Ganirest) is an injectable competitive gonadotropin-releasing hormone (GnRH) antagonist. Ganirelix ac
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.